# Lyell Immunopharma, Inc. (LYEL): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Lyell Immunopharma, Inc. (LYEL) is 7/100, ranked against 24,000+ stocks in 35 markets (Quality 18, Value 32, Momentum 27, each scored against its sector).

- StockRank: 7/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 18, Value 32, Momentum 27: each a 0-100 percentile within Healthcare.
- Position: #24,666 overall, #2,423 in Healthcare.
- Listing: United States, NMS; Healthcare / Biotechnology.
- Last close: 9.31 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors sold USD 255K; 5%+ holders sold USD 274.

Source: https://moatmap.ai/stock/LYEL
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker